Compare AFLAC Incorporated (AFL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Eli Lilly And Co — how do they compare? AFLAC Incorporated trades at $120.52 (market cap $60.70B), while Eli Lilly And Co trades at $1,218.51 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 17.8× AFLAC Incorporated's market cap, and AFLAC Incorporated pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| AFL | LLY | |
|---|---|---|
Market Cap | $60.70B | $1.08T |
Sector | Financials | Health |
52-Week High | $129.55 | $1.24K |
52-Week Low | $103.55 | $639.43 |
Enterprise Value | $70.65B | $1.13T |
Dividend Yield | 2.02% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.94, down 2.14% with bearish technical signals and recent earnings misses. The stock shows strong profitability with 26.59% net margin and 16.91% ROE, but faces revenue declines from $19.1B in 2024 to $17.4B in 2025. Recent news highlights AFL's rebranding efforts and dividend consistency amid healthcare cost pressures. Technical indicators show oversold RSI at 17.69 with support at $117.
Outlook remains cautious with mixed analyst sentiment (28% buy, 56% hold) and $118 consensus target below current price. Risks include Japan market exposure and currency headwinds, balanced by 43-year dividend growth history and strong cash flow generation. The stock offers value at 13x P/E but requires monitoring of revenue stabilization.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
